Cardioselective beta-blockers for chronic obstructive pulmonary disease

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison

“…Whilst CVD is diagnosed in 20 to 60% patients with COPD [ 70 ], our main analysis included primarily small trials and only three explicitly included patients with a cardiac comorbidity (one included angina [ 54 ], two included HF patients [ 55 , 57 ], and one included patients with hypertension, which is a common CVD risk factor [ 50 ]. In line with previous research [ 9 ], we report no significant FEV1 treatment effect in patients with COPD with CVD.…”

“…FEV1 was assessed in 199 patients enrolled in 12 RCTs and we found that none of the individual cardioselective beta-blockers included in our NMA (atenolol, bisoprolol, celiprolol, metoprolol) were associated with significant effects on lung function in patients with COPD, regardless of baseline FEV1 or follow-up time. This is in line with a Cochrane review [ 9 ] which concluded that cardioselective beta-blockers given in either single dose or for longer durations, do not affect FEV1 in patients with COPD, even in those with the lowest baseline FEV1 measurements. Furthermore, our report extends to incorporate a lack of effect on FEV1 of non-selective beta-blockers such as carvedilol and labetalol.…”

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison

“…Whilst CVD is diagnosed in 20 to 60% patients with COPD [ 70 ], our main analysis included primarily small trials and only three explicitly included patients with a cardiac comorbidity (one included angina [ 54 ], two included HF patients [ 55 , 57 ], and one included patients with hypertension, which is a common CVD risk factor [ 50 ]. In line with previous research [ 9 ], we report no significant FEV1 treatment effect in patients with COPD with CVD.…”

“…FEV1 was assessed in 199 patients enrolled in 12 RCTs and we found that none of the individual cardioselective beta-blockers included in our NMA (atenolol, bisoprolol, celiprolol, metoprolol) were associated with significant effects on lung function in patients with COPD, regardless of baseline FEV1 or follow-up time. This is in line with a Cochrane review [ 9 ] which concluded that cardioselective beta-blockers given in either single dose or for longer durations, do not affect FEV1 in patients with COPD, even in those with the lowest baseline FEV1 measurements. Furthermore, our report extends to incorporate a lack of effect on FEV1 of non-selective beta-blockers such as carvedilol and labetalol.…”

Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD

“…Our results are consistent with this. There was a small effect on expiratory flow measured by FEV 1 , which is consistent with previous studies, 14 but no effect on airflow assessed by FEV 1 /FVC. Airway resistance and specific conductance were unchanged, something which has not been published previously, and β-blockade did not lead to a significant change in end-expiratory lung volume and magnitude of dynamic hyperinflation during exercise.…”

Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach

“…CF patients with hemoptysis typically show a significant decline in lung function in general and FEV 1 in particular. Study subjects did not experience increased dyspnea or feel a reduced effect of beta-2 agonists while on beta-blockade, which is consistent with current literature [Salpeter et al 2005]. Hence, we surmise atenolol may have attenuated the expected decline of FEV 1 by allowing the continued and uninterrupted maintenance of therapeutic CF airway clearance regimens associated with the absence of hemoptysis.…”

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison

“…Whilst CVD is diagnosed in 20 to 60% patients with COPD [ 70 ], our main analysis included primarily small trials and only three explicitly included patients with a cardiac comorbidity (one included angina [ 54 ], two included HF patients [ 55 , 57 ], and one included patients with hypertension, which is a common CVD risk factor [ 50 ]. In line with previous research [ 9 ], we report no significant FEV1 treatment effect in patients with COPD with CVD.…”

“…FEV1 was assessed in 199 patients enrolled in 12 RCTs and we found that none of the individual cardioselective beta-blockers included in our NMA (atenolol, bisoprolol, celiprolol, metoprolol) were associated with significant effects on lung function in patients with COPD, regardless of baseline FEV1 or follow-up time. This is in line with a Cochrane review [ 9 ] which concluded that cardioselective beta-blockers given in either single dose or for longer durations, do not affect FEV1 in patients with COPD, even in those with the lowest baseline FEV1 measurements. Furthermore, our report extends to incorporate a lack of effect on FEV1 of non-selective beta-blockers such as carvedilol and labetalol.…”

Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD

“…Our results are consistent with this. There was a small effect on expiratory flow measured by FEV 1 , which is consistent with previous studies, 14 but no effect on airflow assessed by FEV 1 /FVC. Airway resistance and specific conductance were unchanged, something which has not been published previously, and β-blockade did not lead to a significant change in end-expiratory lung volume and magnitude of dynamic hyperinflation during exercise.…”

Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach

“…CF patients with hemoptysis typically show a significant decline in lung function in general and FEV 1 in particular. Study subjects did not experience increased dyspnea or feel a reduced effect of beta-2 agonists while on beta-blockade, which is consistent with current literature [Salpeter et al 2005]. Hence, we surmise atenolol may have attenuated the expected decline of FEV 1 by allowing the continued and uninterrupted maintenance of therapeutic CF airway clearance regimens associated with the absence of hemoptysis.…”

Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison

“…Whilst CVD is diagnosed in 20 to 60% patients with COPD [ 70 ], our main analysis included primarily small trials and only three explicitly included patients with a cardiac comorbidity (one included angina [ 54 ], two included HF patients [ 55 , 57 ], and one included patients with hypertension, which is a common CVD risk factor [ 50 ]. In line with previous research [ 9 ], we report no significant FEV1 treatment effect in patients with COPD with CVD.…”

“…FEV1 was assessed in 199 patients enrolled in 12 RCTs and we found that none of the individual cardioselective beta-blockers included in our NMA (atenolol, bisoprolol, celiprolol, metoprolol) were associated with significant effects on lung function in patients with COPD, regardless of baseline FEV1 or follow-up time. This is in line with a Cochrane review [ 9 ] which concluded that cardioselective beta-blockers given in either single dose or for longer durations, do not affect FEV1 in patients with COPD, even in those with the lowest baseline FEV1 measurements. Furthermore, our report extends to incorporate a lack of effect on FEV1 of non-selective beta-blockers such as carvedilol and labetalol.…”

Effect of β-blockade on lung function, exercise performance and dynamic hyperinflation in people with arterial vascular disease with and without COPD

“…Our results are consistent with this. There was a small effect on expiratory flow measured by FEV 1 , which is consistent with previous studies, 14 but no effect on airflow assessed by FEV 1 /FVC. Airway resistance and specific conductance were unchanged, something which has not been published previously, and β-blockade did not lead to a significant change in end-expiratory lung volume and magnitude of dynamic hyperinflation during exercise.…”

Beta-blocker management of refractory hemoptysis in cystic fibrosis: a novel treatment approach

“…CF patients with hemoptysis typically show a significant decline in lung function in general and FEV 1 in particular. Study subjects did not experience increased dyspnea or feel a reduced effect of beta-2 agonists while on beta-blockade, which is consistent with current literature [Salpeter et al 2005]. Hence, we surmise atenolol may have attenuated the expected decline of FEV 1 by allowing the continued and uninterrupted maintenance of therapeutic CF airway clearance regimens associated with the absence of hemoptysis.…”